Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial.
Yoshikazu InoueAthol U WellsJin Woo SongZuojun XuHideya KitamuraTakafumi SudaMasaki OkamotoHeiko MüllerCarl CoeckKlaus B RohrMartin R J KolbKevin K BrownPublished in: Respirology (Carlton, Vic.) (2023)
In Asian patients with progressive fibrosing ILDs, nintedanib reduced the rate of decline in FVC with adverse events that were manageable for most patients.
Keyphrases
- interstitial lung disease
- idiopathic pulmonary fibrosis
- end stage renal disease
- multiple sclerosis
- systemic sclerosis
- ejection fraction
- chronic kidney disease
- newly diagnosed
- clinical trial
- peritoneal dialysis
- rheumatoid arthritis
- prognostic factors
- study protocol
- randomized controlled trial
- patient reported outcomes